Blinatumomab is an anti-CD19/anti-CD3 bi-specific T cell engager that is approved to treat acute lymphoblastic leukemia and being studied for use in other indications.
| SparkCures ID | 362 |
|---|---|
| Brand Name | Blincyto® |
| Generic Name | Blinatumomab |
| Treatment Classifications |
|
| Treatment Targets |
View all active clinical trials around the US.
There are no resources, links or videos to display for this treatment.